Minerva

Minerva

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7035.920 (Published 06 April 1996) Cite this as: BMJ 1996;312:920
  1. None Given

    Women treated for Hodgkin's disease in childhood have a very high risk of developing cancer: calculations by the Late Effects Study Group suggest that as many as one third may have developed a breast cancer by the age of 40 (New England Journal of Medicine 1996;334:745-51). This warning is based on extrapolations from a follow up of 1380 children treated between 1955 and 1986, of whom 17 had developed breast cancer and 26 had developed leukaemia. The radiation given as part of the treatment for Hodgkin's disease is thought to be the cause of the later cancers.

    Full screening for genetic defects that make blood clotting more likely (thrombophilia) should be offered to patients under the age of 50 who develop occlusion of the central retinal vein. This recommendation is made in an editorial in the “British Journal of Ophthalmology” (1996;80:194) on the basis of two reports in the journal showing that more than one third of younger patients with this condition were found to have activated protein C resistance. The optimum management for patients with this defect and a retinal vein occlusion is probably long term treatment with warfarin, but further research is needed.

    If islets of Langerhans are immunoisolated in alginate microcapsules they can function as an injectable bioartificial endocrine …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe